Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

IMMvention Therapeutix, Inc., an innovative biotechnology company based in Durham, has announced a strategic collaboration with Novo Nordisk A/S. This partnership aims to co-develop oral therapies for ...

Optimize your clinical trials with Citeline’s Strategic Solutions. Drug development is a lengthy and costly endeavor, often taking 10–15 years and up to $2 billion to bring a therapy to market. To ...

As 2024 concludes, molecular medicine continues its steady 6-7% annual growth, while diversifying its therapeutic landscape. Notably, Q4 brought approvals across gene, cell, and RNA therapies: ...

The trial master file (TMF) has become a growing priority for pharmaceutical companies and regulators alike. Effective TMF management ensures compliance and inspection readiness, making the role of ...

A startup based in Research Triangle Park is making significant strides in transforming the tedious and time-consuming process of sample preparation, which is crucial in laboratory settings. Redbud ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...

XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.

Rick Modi’s background in pharmacy gave him the scientific and analytical chops to pursue an MBA and ultimately lead innovative gene therapy companies.